Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rate-cut optimism, autos push UK stocks higher

Wed, 27th Dec 2023 17:04

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

AstraZeneca up on deal to buy Gracell Biotechnologies

*

Darktrace rises on Lynch's stake disclosure

*

Anglo American rises on report of plan to sell stake in UK mine

Dec 27 (Reuters) - London stocks rose on Wednesday led by a surge in automobiles and parts stocks, while investors latched on to the year-end optimism that major central banks including the Bank of England could begin cutting interest rates early in 2024.

The blue-chip FTSE 100 climbed 0.4% after touching seven-month highs earlier in the session. The FTSE 250 midcap index was up 0.5% to close at its highest level since March 2023.

Automobiles and parts index claimed a six-week high to rise 1.9%, leading the gains among sectors, while the biggest losers were the energy shares that fell 0.3% tracking lower oil prices.

Shares in industrial metal miners added 0.7%, as prices of most base metals rose after data showed manufacturing activity in top consumer China improved last month, while a weak U.S. dollar also lent support to the market.

"The Chinese government is now boosting the industrial side of the things, reverting back from their focus on consumers because that's obviously not working well," said Ipek Ozkardeskaya, senior market analyst at Swissquote Bank.

The FTSE 100 is set to end the year on a higher note, driven by expectations that the Fed could begin cutting rates as early as March, with other central bankers to follow.

In corporate news, Anglo American shares climbed 2.3% and were among the top gainers on FTSE 100 after a report the miner was looking to sell part of its stake in a $9 billion UK mining project.

Darktrace was up 3.6% on news that tech entrepreneur Michael Lynch had disclosed a 3.92% stake in the cyber-security company.

AstraZeneca's shares gained 0.9% after a deal to buy Gracell Biotechnologies for up to $1.2 billion as the pharma company furthers its cell therapy ambitions and boosts its presence in China.

The broader pharma and biotech index advanced 0.6%. (Reporting by Khushi Singh in Bengaluru; Editing by Sonia Cheema, Shailesh Kuber and Barbara Lewis)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.